Results 91 to 100 of about 5,184 (154)

Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study. [PDF]

Nat Commun
Chong KC, Wei Y, Wong CKH, Xiong X, Wang H, Hung CT, Li C, Yam CHK, Chow TY, Guo Z, Li K, Yang A, Mok CKP, Hui DSC, Zhao S, Yeoh EK, Lin G.   +16 more
europepmc   +1 more source

Effectiveness of Nirmatrelvir/Ritonavir in Unvaccinated COVID-19 Patients Treated in the Emergency Department: A Retrospective Propensity-Matched Cohort Analysis. [PDF]

Ther Adv Pulm Crit Care Med
Jehle DVK, Sunesra R, Williams SM, Bilby NJ, Paul KK, Hill K.   +5 more
europepmc   +1 more source

Evaluation of a Protocol Managing the Cyclosporine and Nirmatrelvir/Ritonavir Interaction in Kidney Transplant Recipients. [PDF]

Kidney360
Agtarap K, Giguère P, Deschênes MJ, DeVreese L, McDougall J, Hoar S, Hiremath S.   +6 more
europepmc   +1 more source

Complete Heart Block Triggered by Nirmatrelvir-Ritonavir and Verapamil. [PDF]

JACC Case Rep
Offord E, Nabi M, Mankbadi M, Marchetta A, Rosenthal L.   +4 more
europepmc   +1 more source

Health-related quality of life in immunocompromised adults with mild-moderate COVID-19 treated with nirmatrelvir-ritonavir: results from the randomized, double-blinded EPIC-IC trial. [PDF]

Health Qual Life Outcomes
Mokgokong R, Cislo P, Tudone E, Weinstein E, Cappelleri JC.   +4 more
europepmc   +1 more source

Randomized trial of nirmatrelvir/ritonavir versus placebo for adults with acute COVID-19 to prevent long COVID: PanoramicNOR Trial. [PDF]

Trials
Blomberg B, Myklebust NN, Oppegaard O, Tøndel C, Cox RJ, Iversen A, Lehmann ME, Sandvig A, Dahl TB, Valderhaug VD, Szodoray P, Wilhelmsen M, Kirsebom BE, Glambek M, Kaarbøe O, Aukrust P, Lie RT, Langeland N.   +17 more
europepmc   +1 more source

Budget Impact of Adopting Nirmatrelvir-Ritonavir for Treating COVID-19 in a Large Integrated Healthcare System. [PDF]

Open Forum Infect Dis
Bui DP, Hynes DM, Wong E, Vergun R, Yan L, Li Y, Rajeevan N, Berry K, Lin HM, Huang Y, Govier DJ, Aslan M, Ioannou G, Bajema KL.   +13 more
europepmc   +1 more source

Pharmacovigilance of Drug-Drug Interactions with Nirmatrelvir/Ritonavir. [PDF]

Infect Dis Ther
Hendrick V, Pohorylo E, Merchant L, Gerhart J, Arham IN, Draica F, Quercia R, Ayoub A, Mehta R.   +8 more
europepmc   +1 more source

A Retrospective Observational Study on COVID-19 Patients Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID). [PDF]

Pulm Ther
Murad MM, Atkin SL, Wasif PW, Behzad AA, Husain AMJA, d'Hellencourt FL, Joury J, Aziz MA, Haridy H, Spinardi J, Wang L, Boland F, Kyaw MH, Al-Qahtani M.   +13 more
europepmc   +1 more source

Effectiveness of nirmatrelvir/ritonavir and molnupiravir in reducing the risk of short-term and long-term cardiovascular complications of COVID-19: a target trial emulation study. [PDF]

Nat Commun
Guo Z, Wei Y, Lin G, Jia KM, Boyer C, Wang H, Li C, Hung CT, Yam CHK, Chow TY, Zhao S, Li K, Yang A, Mok CKP, Hui DS, Yeoh EK, Chong KC.   +16 more
europepmc   +1 more source